 |
 |
> The study was conducted at a leading academic institution, utilizing a > well-established and validated rhesus monkey model of Parkinson's disease. > Spheramine(TM), the company's proprietary cell therapy, restored function > in animals that had severe movement impairments. Marked improvement was > also shown using a standard scale for assessment of Parkinson's disease > severity. Improvement was rapidly achieved and maintained after a single > treatment. No immunosuppression was required. Efficacy was undiminished at > the conclusion of the eight-month experiment, indicating the potential for > continued efficacy for substantially longer periods. CAUTION CAUTION CAUTION!!!! What "leading academic institution"? This is gobbledygook. If something like this really worked, every neurologist in the country would know about it. Get *much* more information before spending a dime on this stuff! Best, Bob *********************************** ROBERT A. FINK, M. D., F.A.C.S. Neurological Surgery 2500 Milvia Street Suite 222 Berkeley, CA 94704-2636 USA Phone: (510) 849-2555 FAX: (510) 849-2557 WWW: <http://www.dovecom.com/rafink/> mailto:[log in to unmask] "Ex Tristitia Virtus" ***********************************